Skip to main content

Table 1 Baseline characteristics

From: Impaired energetics and normal myocardial lipids in rheumatoid arthritis and systemic lupus erythematosus: a phosphorous and proton magnetic resonance spectroscopy and cardiovascular magnetic resonance study

  Controls N=12 RA N=16 SLE N=13 P value
Female sex, n (%) 8 (67) 10 (63) 13 (100) 0.05
Age, years 49 ± 15 51 ± 13 43 ± 9 0.18
Hypertension, n (%) 0 3 (19) 2 (16) -
Diabetes, n (%) 0 0 1 (8) -
Hyperlipidaemia, n (%) 0 3 (19) 0 -
BMI, kg/m2 24 ± 3 25 ± 3 27 ± 5 0.12
Chloroquine, n (%) N/A 11 (69) 11 (85) -
Methotrexate, n (%) N/A 15 (94) 1 (8) -
Prednisolone, n (%) N/A 2 (13) 9 (69) -
Leflunomide, n (%) N/A 3 (19) 1 (8) -
Sulfasalazine, n (%) N/A 3 (19) 0 -
Azathioprine, n (%) N/A 0 4 (31) -
Rituximab, n (%) N/A 2 (13) 1 (8) -
DAS28-CRP N/A 5 ± 1 N/A -
SLEDAI (median, IQR) N/A N/A 7 (4-11) -
ESR, mm/hr (median, IQR) N/A 7 (5-10) 10 (4-16) -
CRP, mg/L (median, IQR) 1 (1-1) 5 (2-7) 4 (2-6) <0.001
Duration of disease, years (median, IQR) N/A 11 (7-14) 13 (6-16) -
Duration of DMARDs, years (median, IQR) N/A 7 (5-11) 8 (3-11) -
  1. Continuous data are mean ± SD unless otherwise indicated. Categorical data are frequency (percent) unless otherwise indicated. BMI, body mass index; CRP, C-reactive protein; DAS28-CRP (rheumatoid arthritis disease activity index incorporating 28 swollen and tender joint count as well as the C-reactive protein); ESR, erythrocyte sedimentation rate; IQR, interquartile range; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index